Natalizumab Antibody | AbD21384_hIgG1

//www.bio-rad-antibodies.com/natalizumab-antibody-abd21384-higg1-hca250.html?RenderPageSpecific=1
Natalizumab Antibody | AbD21384_hIgG1 gallery image 1

Human anti natalizumab specificity ELISA

A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated Human anti natalizumab (clone AbD21384_hIgG1) at a concentration of 2 μg/ml, in HISPEC assay diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®

Enlarge
Natalizumab Antibody | AbD21384_hIgG1 gallery image 2

Human anti natalizumab specificity titration ELISA

A microtiter plate was coated over night with natalizumab, human IgG1/kappa or human IgG1/lambda at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated Human anti natalizumab (clone AbD21384_hIgG1) titrated to the given concentrations in PBST, followed by QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®. Data is presented as the mean of three measurements

Enlarge
Natalizumab Antibody | AbD21384_hIgG1 gallery image 3

Human anti natalizumab bridging ELISA for Anti-Drug Antibody (ADA) assay development

A microtitre plate was coated over night with natalizumab at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of Human anti natalizumab, clone AbD21375_hIgG1 (HCA249) or clone AbD21384_hIgG1 (HCA250). Detection was performed using HRP-conjugated natalizumab. HRP-conjugation of natalizumab used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®. Data is presented as the mean of three measurements

Enlarge
Natalizumab Antibody | AbD21384_hIgG1 gallery image 4

Human anti natalizumab inhibits the binding of natalizumab to alpha-4/beta-1 integrin

A microtiter plate was coated over night with alpha-4/beta-1 integrin at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, a pre-incubated mixture of natalizumab (0.3 μg/ml) plus increasing concentrations of Human anti natalizumab in its monovalent Fab format was added (clone AbD21384). Free natalizumab, still capable of binding to the alpha-4/beta-1 integrin coated plate, was detected using Mouse anti Human IgG (Fc) CH2 domain:HRP (MCA647P) and QuantaBlu fluorogenic peroxidase substrate. Data is presented as the mean of three measurements

Enlarge
  • Natalizumab Antibody | AbD21384_hIgG1 thumbnail image 1
  • Natalizumab Antibody | AbD21384_hIgG1 thumbnail image 2
  • Natalizumab Antibody | AbD21384_hIgG1 thumbnail image 3
  • Natalizumab Antibody | AbD21384_hIgG1 thumbnail image 4
  • Human anti Natalizumab
(Rated 0.0 out of 5 based on 0 customer reviews)
    Anti-natalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for natalizumab and biosimilars. It is recommended as a reference standard with medium affinity for an ADA bridging ELISA.
    • Product Type
      Monoclonal Antibody
    • Clone
      AbD21384_hIgG1
    • Isotype
      IgG1
    1 Formats Available
      Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
      HCA250Edatasheet pdfdatasheet pdf0.1 mg
      HCA250
      Summary
      Secondary Antibodies
      Negative Isotype Controls
      Useful Reagents
      Positive Controls
      Histology Controls
      More Images
      References
      Reviews
      -
      • Human anti natalizumab, clone AbD21384_hIgG1 is a Type 1 anti-idiotypic antibody that specifically recognizes free natalizumab but not free human alpha4-beta1 integrin or the drug/ alpha4-beta1 integrin complex. Clone AbD21384_hIgG1 inhibits the binding of natalizumab to alpha4-beta1 integrin and can be used to measure free natalizumab levels in serum from patients. This clone can also be used in the development and calibration of anti-drug antibody (ADA) assays.

        Natalizumab, marketed under the brand name Tysabri®, is a humanized IgG4/kappa monoclonal antibody approved as a monotherapy for the treatment of relapsing forms of multiple sclerosis and for the treatment of Crohn’s disease. Natalizumab is also being evaluated for potential clinical use in the treatment of B-cell malignancies. This therapeutic antibody, directed against alpha-4 integrin (CD49d), binds to alpha-4/beta-1 integrin on the surface of circulating leucocytes. It is believed to act by blocking the interaction of alpha-4/beta-1 integrin with vascular cell adhesion molecule-1 (VCAM-1), preventing the adherence and transport of inflammatory immune cells across the intestinal lining and blood-brain barrier.

        Clone AbD21384_hIgG1 is one of a range of Type 1 (HCA248, HCA249), anti-idiotypic antibodies to natalizumab available from Bio-Rad and forms part of a wider and expanding portfolio of anti-idiotypic antibodies that have been developed for the detection of biotherapeutics.
      • Intended Use
      • Product Form
        Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
      • Reconstitution
      • Preparation
        Purified IgG prepared by affinity chromatography on Protein A
      • Preservative Stabilisers
        0.01% Thiomersal
      • Immunogen
        Natalizumab
      • Purity
      • Affinity
        The monovalent intrinsic affinity of this antibody was measured as KD = 12.2 nM by real time, label free molecular interaction analysis on immobilized natalizumab.
      • Approx. Protein Concentrations
        Antibody concentration 0.5 mg/ml
      • Reagents In The Kit
      • Preparing The Antibody
      • Test Principle
      • Buffer Solution
        Phosphate buffered saline
      • Storage
        Store at +4oC or at -20oC if preferred.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use
      • Shelf Life
        12 months from date of despatch
      • Acknowledgements
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents.

        This antibody was developed by Bio-Rad, a wholly owned subsidiary of Bio-Rad Laboratories Inc., Zeppelinstr. 4, 82178 Puchheim, Germany.

        Tysabri is a registered trademark Biogen Idec and Élan.
      • Licensed Use
        For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
      • Regulatory
        For research purposes only
      • This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

      • Application NameYesNoMin DilutionMax Dilution
        ELISA

      • Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Recommended Protocol
      • ELISA
        This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA248 as the capture reagent.
        Protocol: PK bridging ELISA to measure free drug
        This antibody is fully human and can be used as a reference standard in an ADA assay.
        Protocol: ADA bridging ELISA
      • Immunohistology
      • Histology Positive Control Tissue
      • Immunofluorescence
      • Western Blotting
      • Instructions For Use

      Additional Natalizumab Antibody Formats

      Formats Clone Applications Sizes available
      Natalizumab Antibody : Purified AbD21384_hIgG1 E 0.1 mg
      • Copyright © 2016 Bio-Rad

      Recommended Secondary Antibody

        Recommended Negative Isotype Control

          Useful Reagents

            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            Mouse anti Human IgG (Fc) CH2 Domain:HRPMCA647P0.2 mgC *, E
            MCA647P
            LYNX Rapid HRP Antibody Conjugation KitLNK005P1 Conjugation For 20mg AntibodyCJ
            LNK005P
            LYNX Rapid HRP Antibody Conjugation KitLNK001P1 Conjugation For 400µg AntibodyCJ
            LNK001P
            LYNX Rapid HRP Antibody Conjugation KitLNK003P1 Conjugation For 4mg AntibodyCJ
            LNK003P
            LYNX Rapid HRP Antibody Conjugation KitLNK006P3 Conjugations For 40µg AntibodyCJ
            LNK006P
            LYNX Rapid HRP Antibody Conjugation KitLNK002P3 Conjugations For 400µg AntibodyCJ
            LNK002P
            LYNX Rapid HRP Antibody Conjugation KitLNK004P5 Conjugations For 4mg AntibodyCJ
            LNK004P
            Human anti NatalizumabHCA2480.1 mgE
            HCA248
            Human anti NatalizumabHCA2490.1 mgE
            HCA249
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A

            Recommended Positive Controls

              Histology Controls

                Write your review

                You may also be interested in...